Search research articles
Contact Us
Filters
Showing results (1-10 of 104) with videos related to
Page
of 11
Sort By:
Arzneimittel-Forschung
|
August 1, 1975
[MASCA-model of the biochemical-pharmacological drug research. Part 2: Multivariate test criterions and methods (author's transl)]
P P Mager
Medicinal Research Reviews
|
June 19, 2001
The active site of HIV-1 protease
P P Mager
Arzneimittel-Forschung
|
November 1, 1975
[MASCA-model of the biochemical-pharmacological drug research / part 5: Structure-activity relationships and MACOVA (author's transl)]
P P Mager
Pharmazie in Unserer Zeit
|
September 1, 1988
[Optimization of the bioactive lead structure. II. Verification of the system]
P P Mager
Activitas Nervosa Superior
|
May 1, 1975
The discrimination in time series analysis - a working procedure
P P Mager
Tierarztliche Praxis
|
January 1, 1976
[Classification of drug side-effects]
P P Mager
Drug Design and Discovery
|
April 1, 1994
Interactive multivariate modelling of 4-amino-2-carboxytetrahydroquinolines as antagonists of the glycine-site directed NMDA receptor-ion channel complex
P P Mager
Activitas Nervosa Superior
|
March 1, 1983
Indirect discrimination of type 1 mu and 1 delta opioid receptor properties using quantitative structure-activity relationships
P P Mager
Gegenbaurs Morphologisches Jahrbuch
|
January 1, 1980
Structure-activity relationships of interactions of thyroxine analogs with intact hepatic nucleic receptors
P P Mager
Drug Design and Discovery
|
December 1, 1996
Molecular simulation of the folding patterns of the omega-loop (Tyr181 to Tyr188) of HIV-1 reverse transcriptase
P P Mager
Page
of 11
Search research articles
Search
Showing results (1-10 of 104) with videos related to
Sort By:
Page
of 11
Arzneimittel-Forschung
|
August 1, 1975
[MASCA-model of the biochemical-pharmacological drug research. Part 2: Multivariate test criterions and methods (author's transl)]
P P Mager
Medicinal Research Reviews
|
June 19, 2001
The active site of HIV-1 protease
P P Mager
Arzneimittel-Forschung
|
November 1, 1975
[MASCA-model of the biochemical-pharmacological drug research / part 5: Structure-activity relationships and MACOVA (author's transl)]
P P Mager
Pharmazie in Unserer Zeit
|
September 1, 1988
[Optimization of the bioactive lead structure. II. Verification of the system]
P P Mager
Activitas Nervosa Superior
|
May 1, 1975
The discrimination in time series analysis - a working procedure
P P Mager
Tierarztliche Praxis
|
January 1, 1976
[Classification of drug side-effects]
P P Mager
Drug Design and Discovery
|
April 1, 1994
Interactive multivariate modelling of 4-amino-2-carboxytetrahydroquinolines as antagonists of the glycine-site directed NMDA receptor-ion channel complex
P P Mager
Activitas Nervosa Superior
|
March 1, 1983
Indirect discrimination of type 1 mu and 1 delta opioid receptor properties using quantitative structure-activity relationships
P P Mager
Gegenbaurs Morphologisches Jahrbuch
|
January 1, 1980
Structure-activity relationships of interactions of thyroxine analogs with intact hepatic nucleic receptors
P P Mager
Drug Design and Discovery
|
December 1, 1996
Molecular simulation of the folding patterns of the omega-loop (Tyr181 to Tyr188) of HIV-1 reverse transcriptase
P P Mager
Page
of 11